Promising Agent Shows Significant Activity in Patients with Advanced Systemic Mastocytosis
December 14th 2017Results of a phase I trial presented showed that the agent BLU-285 (Avapritinib) agent was well tolerated among patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells.